Peptide
Goserelin (Zoladex)
Goserelin is a synthetic decapeptide GnRH agonist. FDA-approved in 1989, it is used for prostate cancer, breast cancer, and endometriosis. Clinical trials show 82% objective response in metastatic prostate cancer and 10-year survival rates of 42-87% depending on setting. Available as 3.6mg (monthly) and 10.8mg (3-month) subcutaneous implants.
- Updated
- How we grade
- 41 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 2
- Outcomes
- 11
- Graded outcomes
- 6230
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
Key findings
- Disease Control (Breast)Improves (the measure goes up)
- Overall Survival (Prostate)Improves (the measure goes up)
- Testosterone SuppressionImproves (the measure goes down)
Studies cited
41 studies from PubMed
- Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer.
- Multicenter, prospective, single-arm clinical study to investigate the efficacy and safety of Zoladex (Goserelin acetate) 10.8 mg prior to surgery in Chinese premenopausal women with symptomatic uterine fibroids.
- Clinical efficacy and safety of trimonthly administration of goserelin acetate 10.8 mg in premenopausal Chinese females with symptomatic adenomyosis: a prospective cohort study.
- Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review.
- Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety
- Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
- Use of Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy
- Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer.
- Spontaneous reports of seizure in association with leuprolide (lupron depot), goserelin (zoladex implant), and naferelin (synarel nasal spray).
- Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
- Failure of ovarian ablation with goserelin in a pre-menopausal breast cancer patient resulting in pregnancy: a case report and review of the literature.
- Adjuvant goserelin in premenopausal patients with early breast cancer: Results from the ZIPP study
- Goserelin as adjuvant hormonal therapy in premenopausal breast cancer patients
- Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.
- Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer.
- Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial.
- Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer.
- Acute goserelin administration inhibits gonadotropin and androgen secretion in post-menopausal women with ovarian hyperandrogenism.
- Goserelin plus tamoxifen for premenopausal breast cancer
- 10-year follow-up of prostate cancer patients treated with goserelin implant: results from a large multicenter study
- [Clinical uses of goserelin in gynecologic diseases and its safety].
- Comparison of goserelin and leuprolide in combined androgen blockade therapy.
- Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group
- Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.
- Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer
- Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group
- A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
- Catamenial epilepsy and goserelin.
- Zoladex (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy.
- Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions
- Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer.
- Catamenial epilepsy and goserelin.
- Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
- Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
- Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer
- Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
- Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
- Zoladex in advanced breast cancer.
- Zoladex: therapeutic effects in postmenopausal breast cancer.
- Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
- Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.